Abeona Therapeutics, a biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The company offers MuGard, a mucoadhesive oral wound rinse for mucositis, stomatitis, aphthous ulcers, and traumatic ulcers; and ProctiGard, a mucoadhesive oral wound rinse for the treatment of rectal mucositis and radiation proctitis. Its lead program is an adeno-associated virus (AAV)-based gene therapy for sanfilippo syndrome. The company develops ABO-101 for Mucopolysaccharidosis (MPS) III, a sanfilippo syndrome Type B; ABO-102 for MPS III, a sanfilippo syndrome Type A; ABO-201 for juvenile batten disease; ABO-301 for fanconi anemia; and clustered, regularly interspaced short palindromic repeats (CRISPR)-CRISPR associated protein 9 AAV for rare blood diseases. It also develops PTB-101 salt diafiltration process (SDF) Alpha, a alpha1-proteinase inhibitor for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe deficiency of alpha1-proteinase inhibitor; and PTB-102 SDF IVIG, an intravenous immunoglobulin for autoimmune, infectious, and idiopathic diseases. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.
(Summary) (Company) (Chart)
| 4 September 2017 Price $13.80 1yr Target $19.40 Analysts 5 Dividend $0.00 Payout Ratio 0.00% 1yr Cap Gain 40.57% Yield 0.00% 1yr Tot Return 40.57% P/E --- PEG --- Beta 2.28 | EPS (ttm) $-0.60 EPS next yr $-0.76 Forward P/E --- EPS next 5yr --- 1yr Price Support --- Market Cap $589.81 Mil Revenues $0.80 Mil Earnings $-23.20 Mil Profit Margin --- Quick Ratio 14.00 Current Ratio 14.00 Debt/Equity 0.00 | 1yr RevGR -14.52% 3yr RevGR -24.00% 5yr RevGR -13.54% 1yr EarnGR --- 3yr EarnGR --- 5yr EarnGR --- 1yr DivGR --- 3yr DivGR --- 5yr DivGR --- ROA -23.90% ROE -26.70% |
10px
My Path Forward
I started buying these shares as they moved above $11 per share and posted a new all time high. Since then I've been adding more shares as I continue to fill out this position in my portfolio. This appears to be a very strong high growth stock in a sector that is exploding. I intend to continue to add shares in this company as well as other biotech companies in the near future. I believe we are on the cusp os a biotech revolution that will continue for decades. I intend to own shares of those companies that appear to be at the forefront of upcoming technologies. This company appears to be one of them.
I started buying these shares as they moved above $11 per share and posted a new all time high. Since then I've been adding more shares as I continue to fill out this position in my portfolio. This appears to be a very strong high growth stock in a sector that is exploding. I intend to continue to add shares in this company as well as other biotech companies in the near future. I believe we are on the cusp os a biotech revolution that will continue for decades. I intend to own shares of those companies that appear to be at the forefront of upcoming technologies. This company appears to be one of them.
Print 
PDF
RSS Feed
